{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/squint-in-children/prescribing-information/atropine-eye-drops/","result":{"pageContext":{"chapter":{"id":"a7c5d55f-375b-53c4-8c96-a6800e9816ec","slug":"atropine-eye-drops","fullItemName":"Atropine eye drops","depth":2,"htmlHeader":"<!-- begin field e7a55e58-9a68-49a2-a9de-a993fc13b02d --><h2>Atropine eye drops</h2><!-- end field e7a55e58-9a68-49a2-a9de-a993fc13b02d -->","summary":"","htmlStringContent":"<!-- begin item 4954b14a-79a0-48a3-9d6b-6e4538e62651 --><!-- end item 4954b14a-79a0-48a3-9d6b-6e4538e62651 -->","topic":{"id":"d25cf803-28cb-5afd-80ca-d97838356e0c","topicId":"3e67bea0-6e2a-4f62-86eb-6e4c56360437","topicName":"Squint in children","slug":"squint-in-children","lastRevised":"Last revised in January 2021","chapters":[{"id":"b8612b38-b5db-56e8-a543-71e5c697b321","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"780c39cc-055a-53cd-bf74-acd28cc88602","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"afd01e9a-2008-5a2c-9539-10fa84545764","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"6b8c8d6d-89ab-5ea0-ae30-60da95a35e26","slug":"changes","fullItemName":"Changes"},{"id":"3384a548-18ca-5700-81ca-97f085fa4a41","slug":"update","fullItemName":"Update"}]},{"id":"262d6d12-f189-50fe-be83-dc3f7b819c28","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"a04252dd-0eab-51c1-96c3-78aabd585484","slug":"goals","fullItemName":"Goals"},{"id":"ed0abb87-47b9-5dc2-a23a-490395a37a51","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"7ce7f3fa-3b9f-5026-a148-0ea285406c0c","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5250eccf-4fbc-5a72-bab0-669c03e06c58","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0c7cb979-a236-5b84-99c7-2b9fab653503","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d07341e2-26e8-5f76-a64c-4df297389460","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"1b07638c-cefc-5490-8cec-36a5ae1edf50","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5b4456f3-a699-5733-9492-ab8814081a94","slug":"definition","fullItemName":"Definition"},{"id":"64d3ddca-f1f5-56a1-aa00-e77881d13b5b","slug":"classification","fullItemName":"Classification"},{"id":"a95becad-fc39-5213-a78c-6c3a3fb83ec7","slug":"prevalence","fullItemName":"Prevalence"},{"id":"924bf7e2-6ba1-5f39-9369-d7f421d0db43","slug":"causes","fullItemName":"Causes"},{"id":"7f997f2c-42bc-5372-bc69-68390cfdf9b8","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"679ef8e8-d648-55c5-8ce8-7670d6e927f5","slug":"complications","fullItemName":"Complications"},{"id":"546d7400-5c56-5e32-a702-25a6038faa1b","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"683d19f2-df00-5f12-afbb-464c10699f5f","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"2559b5e2-6604-5ca4-b15e-d51eb712aee4","slug":"identification","fullItemName":"Identification"},{"id":"ea4d4c60-e84d-5f2f-8759-12f2223894f3","slug":"assessment","fullItemName":"Assessment"}]},{"id":"2072ffc3-2703-5559-ae10-906f961f9c23","fullItemName":"Management","slug":"management","subChapters":[{"id":"3c959293-ed07-5a6e-b857-6ca0fad7a1a3","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"ab53d1f3-0839-5c38-a7c2-7dc1dcd0d403","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a7c5d55f-375b-53c4-8c96-a6800e9816ec","slug":"atropine-eye-drops","fullItemName":"Atropine eye drops"}]},{"id":"bca67f8e-d20f-5aa6-9128-e06b4801b3df","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"195f7f07-a039-5ad4-9619-47ec9f7a17b6","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d19c577a-210d-56ee-a016-2fc7fdb391d3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"96115e23-6d19-55a0-9659-317f379833d5","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3ae1b903-9fac-5f81-99f0-ae27261c65be","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"3c6a1cf1-fa3d-589e-a984-9c99b716da6c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"a8402308-0a8f-50c4-9974-22016c1078cb","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"bf5d047c-4b2c-5972-993d-649c64937fba","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ab53d1f3-0839-5c38-a7c2-7dc1dcd0d403","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"45caa77a-4fc9-5f83-83bb-f7318151bb1f","slug":"mode-of-action","fullItemName":"Mode of action","depth":3,"htmlHeader":"<!-- begin field 21971d6c-e802-4f91-9404-c38efd99e483 --><h3>How do atropine eye drops work for treating amblyopia?</h3><!-- end field 21971d6c-e802-4f91-9404-c38efd99e483 -->","summary":"","htmlStringContent":"<!-- begin item 9fe19fda-7a69-41d1-92b8-44cb79bc48b7 --><!-- begin field c412aaae-440d-4e39-9d69-fbca55d65245 --><ul><li><strong>Atropine sulfate is an antimuscarinic drug used as a cycloplegic (to induce paralysis of the ciliary muscle of the eye) in the management of children with a <a class=\"topic-reference internal-reference\" href=\"/topics/squint-in-children/background-information/classification/\">convergent squint</a>. </strong><ul><li>Cycloplegia results in a loss of accommodation, so the child then prefers to use the amblyopic eye rather than the blurred image from the normal eye.</li></ul></li><li>Atropine is long lasting and may not need to be instilled every day. Regimens vary, and the drops may only be needed to be instilled 2–3 times a week.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/squint-in-children/references/\">ABPI, 2016</a>]</p><!-- end field c412aaae-440d-4e39-9d69-fbca55d65245 --><!-- end item 9fe19fda-7a69-41d1-92b8-44cb79bc48b7 -->","subChapters":[]},{"id":"2fc47b90-445a-501b-bead-07eac55a0f06","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 10940f5f-0a2c-45e9-9e08-f737a2e9d7ea --><h3>What are the contraindications and cautions for atropine eye drops?</h3><!-- end field 10940f5f-0a2c-45e9-9e08-f737a2e9d7ea -->","summary":"","htmlStringContent":"<!-- begin item 621aef4a-6659-4ad3-ac5b-aba6aee29276 --><!-- begin field 18b41d00-d216-442d-aaaa-4fd8a18daafb --><ul><li><strong>Atropine eye drops should not be used in people:</strong><ul><li>With known hypersensitivity to any component of the preparation.</li><li>Known to have a narrow angle between the iris and the cornea — may precipitate an acute attack of closed angle glaucoma (although this is extremely unusual in children).</li><li>With closed angle glaucoma.</li></ul></li><li><strong>Atropine eye drops should be used with caution in people who have:</strong><ul><li>Raised intraocular pressure.</li><li>Conditions that cause tachycardia.</li></ul></li></ul><div><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/squint-in-children/references/\">ABPI, 2016</a>]</p></div><!-- end field 18b41d00-d216-442d-aaaa-4fd8a18daafb --><!-- end item 621aef4a-6659-4ad3-ac5b-aba6aee29276 -->","subChapters":[]},{"id":"af2e906e-f8b6-5bcf-baa0-c81445edbffe","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 88ec567c-fd60-486a-b2dc-805cb7fc918b --><h3>What are the possible adverse effects of atropine eye drops?</h3><!-- end field 88ec567c-fd60-486a-b2dc-805cb7fc918b -->","summary":"","htmlStringContent":"<!-- begin item ac7de2f3-f7e3-4398-9382-af14da56f349 --><!-- begin field 75990d2a-4f6a-4141-b258-89327b41d191 --><ul><li><strong>Local adverse effects that sometimes occur include:</strong><ul><li>Photophobia — advise that the eye should be protected from bright light while the pupils are dilated. </li><li>Local irritation, transient stinging, hyperaemia, oedema, and conjunctivitis (with prolonged use of the eye drops).</li><li>Increased intra-ocular pressure (especially in people with closed angle glaucoma).</li><li>Rash on eyelids or surrounding skin due to hypersensitivity.</li></ul></li><li><strong>Systemic adverse effects are uncommon.</strong> Those reported include:<ul><li>Ataxia.</li><li>Restlessness and excitement.</li><li>Confusion.</li><li>Giddiness.</li><li>Hallucinations. </li><li>Dry mouth (with difficulty in swallowing and talking).</li><li>Flushing and dry skin.</li><li>Transient bradycardia, followed by tachycardia, palpitations, and arrhythmias.</li><li>Urinary urgency and retention.</li><li>Constipation. </li><li>Nausea and vomiting.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/squint-in-children/references/\">ABPI, 2016</a>]</p><!-- end field 75990d2a-4f6a-4141-b258-89327b41d191 --><!-- end item ac7de2f3-f7e3-4398-9382-af14da56f349 -->","subChapters":[]},{"id":"440cb895-8814-5138-8b66-bc5f8e868fa1","slug":"interactions","fullItemName":"Interactions","depth":3,"htmlHeader":"<!-- begin field a663059d-504f-4141-8eff-44587b5e7472 --><h3>What are the possible drug interactions with atropine eye drops?</h3><!-- end field a663059d-504f-4141-8eff-44587b5e7472 -->","summary":"","htmlStringContent":"<!-- begin item e1134c6d-35f3-4933-a87a-f41ae8535c87 --><!-- begin field 704ce8e1-acf0-40f6-b658-5e5f93283f1a --><ul><li>The effects of atropine may be enhanced by the concurrent use of other drugs with antimuscarinic properties.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/squint-in-children/references/\">ABPI, 2016</a>]</p><!-- end field 704ce8e1-acf0-40f6-b658-5e5f93283f1a --><!-- end item e1134c6d-35f3-4933-a87a-f41ae8535c87 -->","subChapters":[]},{"id":"9ce6b61d-0abd-5505-ae94-ae33304558b0","slug":"information-for-parents-carers","fullItemName":"Information for parents/carers","depth":3,"htmlHeader":"<!-- begin field 62d62ba8-0515-4347-add0-aca800ca8d6b --><h3>What should I advise the parents/carers?</h3><!-- end field 62d62ba8-0515-4347-add0-aca800ca8d6b -->","summary":"","htmlStringContent":"<!-- begin item c3135ec2-5510-49f0-a0bb-ac03d8800c7a --><!-- begin field 005694a8-9d69-4791-9cad-aca800ca8d6b --><ul><li><strong><strong><strong><strong><strong>Advise the parents or carers that:</strong></strong></strong></strong></strong><ul style=\"font-weight: 400;\"><li>Hands should be washed after using the eye drops and great care should be taken to avoid getting drops into the mouth.</li></ul><ul><li>Care should be taken not to touch the dropper nozzle on to the eyelid or any other surface.</li></ul><ul style=\"font-weight: 400;\"><li>Due to the risk of provoking hyperpyrexia, atropine eye drops should be used with caution when the ambient temperature is high, or the child has a fever. </li></ul></li><li><strong><strong>Remind them that:</strong></strong><ul><li>The drops are to be used in the child's good seeing eye and not in their amblyopic eye.</li><li>That the eye drops will temporarily impair vision.</li><li>The eye drops should be discarded 4 weeks after first opening.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/squint-in-children/references/\">ABPI, 2016</a>]</p><!-- end field 005694a8-9d69-4791-9cad-aca800ca8d6b --><!-- end item c3135ec2-5510-49f0-a0bb-ac03d8800c7a -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}